[Gastrointestinal cancer antigen and carcinoembryonic antigen in chronic pancreatopathies and pancreatic tumors].
Sensitivity and specificity of the Ca 19-9 (GICA) marker was evaluated in series of pancreatic cancer patients, chronic pancreatitis patients and normal controls. When Ca 19-9 was compared with CEA, it was noted that the new marker was far more sensitive and specific than CEA (82% v. 52% sensitivity, 95% v. 80% specificity). GICA was found to be the best marker for pancreatic tumors.
D000911:Antibodies, Monoclonal / Q000276:immunology*; D000936:Antigen-Antibody Complex / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D002908:Chronic Disease; D003110:Colonic Neoplasms / Q000276:immunology; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D010195:Pancreatitis / Q000276:immunology*; D012004:Rectal Neoplasms / Q000276:immunology
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D002272:Carcinoembryonic Antigen; D005732:Gangliosides
Gastrointestinal cancer antigen (GICA) e carcino embryonic antigen (CEA) nelle pancreatopatie croniche e nel tumore pancreatico.